TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05941312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous products
Description: After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous products
Description: After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous products
Description: After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous products
Description: After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
Study: NCT00302653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Rasburicase 0,20mg/Kg/Day once a day 3-7 days
Study: NCT03222310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib 100 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 100 mg capsules orally once daily.
Study: NCT00349778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
Study: NCT02975674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT-12 dental implant
Description: Placement of the MT-12 dental implant with Morse taper implant-abutment connection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CON.INT dental implant
Description: Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
Study: NCT02462018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WalkAide
Description: Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES.
Study: NCT01076387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open radical cystectomy
Description: Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted radical cystectomy
Description: Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
Study: NCT00681733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 1200 mg/d
Study: NCT02679287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLC
Description: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLC
Description: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
Study: NCT01732016

Intervention type: OTHER
Group type: OTHER
Intervention: Normobaric hypoxia chamber
Study: NCT01725594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02303028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan and Pazopanib
Description: Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
Study: NCT02300740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: NIAGEN, ChromaDex

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: NIAGEN, ChromaDex
Study: NCT03051308

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation
Study: NCT03320135

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivative proteins
Description: Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap debridement
Description: Open flap debridement will be performed to decontaminate the proximal furcation involvements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap debridement
Description: Open flap debridement will be performed to decontaminate the proximal furcation involvements.
Study: NCT01602068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic
Description: Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mM Sodium Citrate Buffer
Description: Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
Study: NCT00287612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap. Fundo. with Mobilization of the Esophageal Junction
Description: Complete mobilization of the esophageal junction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lap. Fundo. without Mobilization of the Esophageal Junction
Description: phrenoesophageal membrane left intact
Study: NCT02109965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
Study: NCT02624713

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: obesity treatment
Description: 1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. .

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: obesity treatment
Description: 1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. .
Study: NCT02316652

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Mechanical instrumentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing with solution
Description: Mechanical instrumentation with sodium hypochlorite disinfective solution
Study: NCT01363999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: single dose of atorvastatin on day 1
Study: NCT01602900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolipram
Description: Challenge Agent
Study: NCT00728325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Description: SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vocational Rehabilitation (VRP)
Description: Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
Study: NCT01363999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: single dose of atorvastatin on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: single dose of atorvastatin on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: single dose of atorvastatin on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: single dose of dalcetrapib on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: single dose of dalcetrapib on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: single dose of dalcetrapib on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: single dose of dalcetrapib on day 1
Study: NCT02134873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
Study: NCT01809028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA with 2 passes
Description: biopsy with 2 passes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS FNA with 4 passes
Description: biopsy with 4 passes
Study: NCT05267964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epping resection arthroplasty
Description: Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CMC I prosthesis
Description: Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
Study: NCT01657994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined functional electrical stimulation and robotic gait training
Description: up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
Study: NCT02885506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
Study: NCT02597556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
Study: NCT04297930

Intervention type: DEVICE
Intervention: Paul Glaucoma Implant Surgery
Description: This group of patients had glaucoma surgery with the Paul Glaucoma Implant
Study: NCT01982253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fasiglifam
Description: Fasiglifam placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to fasiglifam
Description: Fasiglifam placebo-matching tablets
Study: NCT04374006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: 1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
Study: NCT00913744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: ocriplasmin intravitreal injection (125 µg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection
Study: NCT02808286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid
Description: The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet Cognitive Behavior Therapy (iCBT)
Description: A state-of-the-art CBT pain treatment, delivered via the internet.
Study: NCT01275495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Assessment and Skill-Building Kit (TASK II)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information, Support, and Referral (ISR)
Study: NCT01978314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 75 mg / 6 mL VFI™
Description: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Study: NCT02061969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: 5mg linagliptin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine